

3.1 患者背景一覽表

3.1.1 患者背景一覽

患者背景		血縁者間 骨髓移植	血縁者間末梢血 幹細胞移植	非血縁者間 骨髓移植	臍帯血移植	合計
患者数		1452	1624	3433	2433	8942
性別	男	814 (56.1%)	956 (58.9%)	2040 (59.4%)	1409 (57.9%)	5219 (58.4%)
	女	638 (43.9%)	668 (41.1%)	1393 (40.6%)	1024 (42.1%)	3723 (41.6%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
年齢	0-17	462 (31.8%)	138 (8.5%)	498 (14.5%)	449 (18.5%)	1547 (17.3%)
	18-55	784 (54.0%)	1082 (66.6%)	2123 (61.8%)	1275 (52.4%)	5264 (58.9%)
	56-	206 (14.2%)	404 (24.9%)	811 (23.6%)	709 (29.1%)	2130 (23.8%)
	不明・未記載	0 (0.0%)	0 (0.0%)	1 (0.0%)	0 (0.0%)	1 (0.0%)
診断	AML	442 (30.4%)	616 (37.9%)	1299 (37.8%)	1113 (45.8%)	3470 (38.8%)
	ALL	367 (25.3%)	277 (17.1%)	674 (19.6%)	451 (18.5%)	1769 (19.8%)
	ATL	46 (3.2%)	84 (5.2%)	170 (5.0%)	74 (3.0%)	374 (4.2%)
	CML	36 (2.5%)	39 (2.4%)	94 (2.7%)	63 (2.6%)	232 (2.6%)
	MDS	122 (8.4%)	143 (8.8%)	362 (10.5%)	201 (8.3%)	828 (9.3%)
	NHL	112 (7.7%)	247 (15.2%)	356 (10.4%)	237 (9.7%)	952 (10.7%)
	固形腫瘍	30 (2.1%)	24 (1.5%)	6 (0.2%)	45 (1.9%)	105 (1.2%)
	その他	297 (20.5%)	194 (12.0%)	472 (13.8%)	249 (10.2%)	1212 (13.6%)
移植時病期	CR	655 (45.3%)	603 (37.5%)	1674 (48.9%)	882 (36.4%)	3814 (42.8%)
	Non-CR	521 (36.1%)	893 (55.5%)	1431 (41.8%)	1334 (55.0%)	4179 (46.9%)
	その他	229 (15.9%)	63 (3.9%)	266 (7.8%)	135 (5.6%)	693 (7.8%)
	不明・未記載	40 (2.8%)	49 (3.1%)	55 (1.6%)	73 (3.0%)	217 (2.4%)
BU剤型	BU (経静脈)を含むレジメン	300 (89.8%)	484 (78.4%)	938 (84.2%)	435 (85.5%)	2157 (83.8%)
	BU (経口)を含むレジメン	34 (10.2%)	133 (21.6%)	176 (15.8%)	74 (14.5%)	417 (16.2%)
前治療レジメン	BU (経静脈)+CY±other	125 (13.2%)	140 (14.4%)	332 (12.2%)	81 (4.3%)	678 (10.4%)
	CY+TBI±other	482 (50.8%)	381 (39.2%)	1256 (46.2%)	715 (37.7%)	2834 (43.3%)
	BU (経静脈)+FL±other	145 (15.3%)	310 (31.9%)	575 (21.2%)	323 (17.0%)	1353 (20.7%)
	FL+TBI±other	197 (20.8%)	141 (14.5%)	556 (20.5%)	780 (41.1%)	1674 (25.6%)
GVHD予防薬	MTX+CyA	821 (56.5%)	791 (48.7%)	597 (17.4%)	685 (28.2%)	2894 (32.4%)
	MTX+FK506	408 (28.1%)	308 (19.0%)	2647 (77.1%)	732 (30.1%)	4095 (45.8%)
	その他	223 (15.4%)	525 (32.3%)	189 (5.5%)	1016 (41.8%)	1953 (21.8%)

略語	
BU	Busulfan
CY	Cyclophosphamide
TBI	Total body irradiation
FL	Fludarabine phosphate